Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe
Authors
Keywords
-
Journal
HIV MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-02-24
DOI
10.1111/hiv.13262
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naïve Persons
- (2021) Alexander J Bailey et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting
- (2020) Lauren Greenberg et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Nothing is perfect: the safety issues of integrase inhibitor regimens
- (2020) Sofía Scévola et al. Expert Opinion On Drug Safety
- First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines
- (2020) Kate El Bouzidi et al. AIDS
- Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors
- (2020) A Borghetti et al. HIV MEDICINE
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2020) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings
- (2020) Daniele Armenia et al. JOURNAL OF CLINICAL VIROLOGY
- Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy
- (2020) Mulugeta Melku et al. Environmental Health and Preventive Medicine
- Is the rate of virological failure to cART continuing to decline in recent calendar years?
- (2019) Stefano Rusconi et al. JOURNAL OF CLINICAL VIROLOGY
- Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
- (2019) Rossana Scutari et al. Journal of Global Antimicrobial Resistance
- Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors
- (2019) Li-Li Yang et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations
- (2019) Francesco Saladini et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
- (2019) Philip L Tzou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors
- (2018) Wendy W Zhang et al. JOURNAL OF INFECTIOUS DISEASES
- Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort
- (2018) S Modica et al. HIV MEDICINE
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
- (2018) Raphael J. Landovitz et al. PLOS MEDICINE
- Tolerability of integrase inhibitors in a real-life setting
- (2017) Judit Peñafiel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy
- (2017) S. Scott Sutton et al. PHARMACOTHERAPY
- Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
- (2016) Anthony T. Podany et al. CLINICAL PHARMACOKINETICS
- Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe
- (2016) Gilles Wandeler et al. Current Opinion in HIV and AIDS
- Brief Report
- (2015) Sharon Walmsley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Dolutegravir in antiretroviral-naive adults with HIV-1
- (2013) Hans-Jürgen Stellbrink et al. AIDS
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
- (2013) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search